Benitec Biopharma Inc.

BNTC | NASDAQ

Price Alert Chart Builder DCF Calculator

$10.88

-$0.14 (-1.27%)

At close: Sep 21, 2026, 4:00 PM ET

$10.88

$0 (0.00%)

After-hours: Sep 21, 2026, 4:10 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-1.27%

(1D)

Rating

Updated: Aug 27, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $373.77M

1D Range

10.74 11.13

52W Range

9.85 16.76

Valuation (TTM)

PE -11.10

PB 2.11

EV/EBITDA -3.84

Valuation (NTM)

Forward PE N/A

Forward PEG -0.45

Price Target $21

Cash Flow

FCF Yield -4.6%

SBC Adj. FCF Yield -9.6%

SBC Impact -110.1%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y 1.6% | 24.0%

Dil EPS 3Y | 5Y 30.9% | 46.5%

FCF 3Y | 5Y 6.3% | -8.3%

Returns

ROA -24.9%

ROE -28.4%

ROIC -28.8%

Financial Health

Net Cash

$179.71M

Current Ratio 34.00

Interest Coverage 21.32

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA int...

Sector Healthcare

Industry Biotechnology

Employees 19

IPO Date Jun 23, 2014

Website benitec.com

Fiscal Year July - June

Full Company Profile

Latest News

No news articles available yet.

Earnings

Latest Earnings

Sep 14, 2026

EPS

-$0.26

Miss 0.00%

YoY: +38.10%

REV

-$833.04K

Miss -106.08%

YoY: -249.83%

Next Earnings

Sep 30, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$21

Upside

+93.01%

Buy (4)

Hold (0)

Sell (0)

Analyst Details ➞